secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2022-03-23T23:59:59+00:00
Accession:  0001683168-22-001853
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic reports FY2021 net loss of $5.6M; royalty revenue up 166% to $1.2M
--------------------------------------------------------------------------

- Net loss for FY2021 was approx $5.6M; R&D expenses rose to $3.2M (vs $1.7M in 2020) on XCART investment.
- Cash at year-end $18.2M; working capital $17.3M, up from $11.4M in 2020.
- Royalty payments from PolyXen platform totaled $1.2M, up 166% YoY, from Takeda sublicensee product launches.
- XCART program advancing toward IND-enabling studies; U.S. patent for co-administration with personalized vaccine issued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316822001853/0001683168-22-001853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316822001853/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-001853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer